|
02 Nov 2018 |
Bavarian Nordic Announces Initiation of Clinical Trial Evaluating the Combination Therapy of CV301 and Durvalumab in Metastatic Colorectal and Pancreatic Cancers
|
|
31 Oct 2018 |
Daiichi Sankyo Announces Discontinuation of Intradermal Seasonal Influenza Vaccine Development in Japan
|
|
30 Oct 2018 |
Generex Biotechnology Announces IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda®) for the Treatment of Triple-Negative Breast Cancer
|
|
25 Oct 2018 |
Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses
|
|
25 Oct 2018 |
Johnson & Johnson Announces Promising, Early-Stage Results for Tetravalent Mosaic-based HIV Preventive Vaccine Regimen
|
|
24 Oct 2018 |
InvVax Achieves Preclinical Milestone with Universal Flu Vaccine Candidate
|
|
23 Oct 2018 |
Trial to provide first-in-human data for CureVac’s novel mRNA-based intramuscular rabies vaccine
|
|
23 Oct 2018 |
Inovio presents progression free survival & PSA doubling time improvements in prostate cancer patients treated with INO-5150
|
|
23 Oct 2018 |
Sellas Life Sciences - SELLAS Life Sciences Announces Positive Final Data in Triple Negative Breast Cancer Patients from Phase 2b Clinical Trial of Nelipepimut-S (NeuVax™) in Combination with Trastuzumab (Herceptin®) Presented at the European Society for
|
|
22 Oct 2018 |
DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration
|
|
19 Oct 2018 |
Sanofi receives positive CHMP opinion for dengue vaccine
|
|
16 Oct 2018 |
Aimmune Therapeutics Announces Initiation of Phase 2 Study With Regeneron and Sanofi of AR101 With Adjunctive Dupilumab in Peanut-Allergic Patients
|
|
16 Oct 2018 |
Targovax Reports Encouraging Disease-free Survival (DFS) Data From Tg01 Trial in Resected Pancreatic Cancer
|
|
16 Oct 2018 |
Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies
|
|
10 Oct 2018 |
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer
|
|
10 Oct 2018 |
IAVI Announces Clinical Trial of Next-Generation HIV Vaccine Candidate Designed to Induce Antibodies to Block HIV Infection
|
|
05 Oct 2018 |
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
|
|
05 Oct 2018 |
FluGen Presents First-in-Human Phase 1a Safety and Immunogenicity Data with Novel M2SR Influenza Vaccine at ID Week
|
|
05 Oct 2018 |
Valneva Announces FDA Approval of Accelerated IXIARO® Vaccination Schedule
|
|
27 Sep 2018 |
ImmusanT Announces First Patient Dosed in Phase 2 Trial of Therapeutic Vaccine for Celiac Disease
|
|
27 Sep 2018 |
OncBioMune Initiates Phase 2 Clinical Trial of Novel Vaccine as Front-Line Treatment for Prostate Cancer
|
|
27 Sep 2018 |
GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study
|
|
21 Sep 2018 |
Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
|
|
21 Sep 2018 |
AIVITA Biomedical Announces Treatment of First Patient in Phase 2 Ovarian Cancer Trial
|
|
19 Sep 2018 |
Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Atezolizumab in Bladder Cancer
|
